These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 32597790)

  • 21. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
    Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
    J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NEDD9 overexpression: Prognostic and guidance value in acute myeloid leukaemia.
    Hua S; Feng T; Yin L; Wang Q; Shao X
    J Cell Mol Med; 2021 Oct; 25(19):9331-9339. PubMed ID: 34432355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Zhang TJ; Zhou JD; Zhang W; Lin J; Ma JC; Wen XM; Yuan Q; Li XX; Xu ZJ; Qian J
    Clin Epigenetics; 2018; 10():47. PubMed ID: 29643943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive analysis of SPAG1 expression as a prognostic and predictive biomarker in acute myeloid leukemia by integrative bioinformatics and clinical validation.
    Gu Y; Chu MQ; Xu ZJ; Yuan Q; Zhang TJ; Lin J; Zhou JD
    BMC Med Genomics; 2022 Feb; 15(1):38. PubMed ID: 35227274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.
    LaRochelle O; Bertoli S; Vergez F; Sarry JE; Mansat-De Mas V; Dobbelstein S; Dastugue N; Strzelecki AC; Cavelier C; Creancier L; Pillon A; Kruczynski A; Demur C; Sarry A; Huguet F; Huynh A; Récher C; Delabesse E
    Oncotarget; 2011 Nov; 2(11):850-61. PubMed ID: 22081665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients.
    Park SH; Choi JC; Kim SY; Yi J; Oh SH; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
    Biomed Res Int; 2015; 2015():723682. PubMed ID: 25650308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
    Marcucci G; Metzeler KH; Schwind S; Becker H; Maharry K; Mrózek K; Radmacher MD; Kohlschmidt J; Nicolet D; Whitman SP; Wu YZ; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Moore JO; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2012 Mar; 30(7):742-50. PubMed ID: 22291079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-196b-TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML.
    Gamlen HA; Romer-Seibert JS; Lawler ME; Versace AM; Goetz ML; Feng Y; Guryanova OA; Palmisiano N; Meyer SE
    Clin Cancer Res; 2022 Oct; 28(20):4574-4586. PubMed ID: 35943291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia.
    Ibrahem L; Mahfouz R; Elhelw L; Abdsalam EM; Soliman R
    Blood Cells Mol Dis; 2015 Jan; 54(1):84-9. PubMed ID: 25172541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia.
    Chu MQ; Zhang TJ; Xu ZJ; Gu Y; Ma JC; Zhang W; Wen XM; Lin J; Qian J; Zhou JD
    J Cell Mol Med; 2020 Jan; 24(2):1640-1649. PubMed ID: 31794134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia.
    Hayette S; Thomas X; Jallades L; Chabane K; Charlot C; Tigaud I; Gazzo S; Morisset S; Cornillet-Lefebvre P; Plesa A; Huet S; Renneville A; Salles G; Nicolini FE; Magaud JP; Michallet M
    PLoS One; 2012; 7(12):e51527. PubMed ID: 23251566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
    Walter MJ; Ding L; Shen D; Shao J; Grillot M; McLellan M; Fulton R; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Kandoth C; Baty J; Westervelt P; DiPersio JF; Mardis ER; Wilson RK; Ley TJ; Graubert TA
    Leukemia; 2011 Jul; 25(7):1153-8. PubMed ID: 21415852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia.
    Zhou JD; Zhang TJ; Xu ZJ; Gu Y; Ma JC; Li XX; Guo H; Wen XM; Zhang W; Yang L; Liu XH; Lin J; Qian J
    Diagn Pathol; 2019 Jun; 14(1):68. PubMed ID: 31253168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AML-Associated Mutations in DNA Methyltransferase DNMT3A.
    Khrabrova DA; Yakubovskaya MG; Gromova ES
    Biochemistry (Mosc); 2021 Mar; 86(3):307-318. PubMed ID: 33838631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients.
    Yuan XQ; Peng L; Zeng WJ; Jiang BY; Li GC; Chen XP
    Medicine (Baltimore); 2016 May; 95(18):e3519. PubMed ID: 27149454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients.
    Yuan XQ; Chen P; Du YX; Zhu KW; Zhang DY; Yan H; Liu H; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Yang J; Zeng WJ; Chen XP
    J Transl Med; 2019 Jul; 17(1):220. PubMed ID: 31291961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
    Thol F; Klesse S; Köhler L; Gabdoulline R; Kloos A; Liebich A; Wichmann M; Chaturvedi A; Fabisch J; Gaidzik VI; Paschka P; Bullinger L; Bug G; Serve H; Göhring G; Schlegelberger B; Lübbert M; Kirchner H; Wattad M; Kraemer D; Hertenstein B; Heil G; Fiedler W; Krauter J; Schlenk RF; Döhner K; Döhner H; Ganser A; Heuser M
    Leukemia; 2017 Jun; 31(6):1286-1295. PubMed ID: 27881874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mutational and expressional analysis of DNMT3A in acute myeloid leukemia cytogenetic subgroups.
    Zare-Abdollahi D; Safari S; Movafagh A; Riazi-Isfahani S; Ghadyani M; Hashemi-Gorji F; Feyzollah HG; Nasrollahi MF; Omrani MD
    Hematology; 2015 Aug; 20(7):397-404. PubMed ID: 25592687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.